ABSTRACT
Evaluation of alopecia often includes laboratory testing for ferritin, thyroid stimulating hormone, vitamin D, and zinc as previous studies have found associations between non-scarring alopecia and vitamin deficiencies. These studies are limited by small sample sizes, and subsequent analyses showed conflicting results. This study aims to explore laboratory abnormalities in non-scarring alopecia and examine whether supplementation is associated with increased hair growth. A total of 131 patients completed at least two visits by a hair specialist at NYU’s Faculty Group Practice. They had quantitative hair measurements taken at each visit and laboratory tests performed at the first visit. There were 20 (15.3%) patients with abnormal lab results. The most common vitamin deficiency was ferritin (6.5%). Forty-two (32%) patients received supplementations that specifically addressed their vitamin or hormone deficiency. Multivariate regression analysis showed that supplementation did not significantly impact hair density or diameter (P=0.73; P=0.96, respectively). Baseline hair density and diameter were positively associated with change in hair density and diameter, respectively (standardized coefficient [β] 0.57, P<0.01; β 0.61, P<0.01). The number of prescribed oral medications was negatively associated with change in hair diameter (β -6.60, P=0.04). Limitations of this study include the single-center, retrospective design and the short followup interval. However, our findings suggest that vitamin supplementation may not lead to improved outcomes in non-scarring alopecia, thus limiting the utility of laboratory testing. Additional large-scale prospective studies are needed to improve our management of alopecia. J Drugs Dermatol. 2021;20(7):807-809. doi:10.36849/JDD.5886.
Subject(s)
Alopecia , Laboratories , Alopecia/diagnosis , Alopecia/drug therapy , Dietary Supplements , Hair , Humans , Retrospective StudiesABSTRACT
Telogen effluvium (TE) – a common cause of non- scarring hair loss – is managed with varying clinical protocols given the paucity of evidence-based practices.
Subject(s)
Alopecia/diagnosis , Anemia, Iron-Deficiency/diagnosis , Hair/physiopathology , Alopecia/blood , Alopecia/etiology , Alopecia/physiopathology , Anemia, Iron-Deficiency/blood , Anemia, Iron-Deficiency/complications , Anemia, Iron-Deficiency/physiopathology , Biomarkers/blood , Ferritins/blood , Hair/growth & development , Humans , Thyrotropin/blood , Vitamins/blood , Zinc/bloodSubject(s)
Dermatologists/statistics & numerical data , Dermatology/statistics & numerical data , Hospitalization/statistics & numerical data , Medicare/economics , Practice Patterns, Physicians'/statistics & numerical data , Cross-Sectional Studies , Dermatology/economics , Dermatology/trends , Geography , Health Services Accessibility/economics , Health Services Accessibility/statistics & numerical data , Health Services Accessibility/trends , Health Workforce/economics , Health Workforce/statistics & numerical data , Health Workforce/trends , Hospitalization/economics , Hospitalization/trends , Humans , Medicare/statistics & numerical data , Practice Patterns, Physicians'/economics , Practice Patterns, Physicians'/trends , Referral and Consultation/economics , Referral and Consultation/statistics & numerical data , Referral and Consultation/trends , United StatesABSTRACT
Melasma is a common acquired condition of symmetric hyperpigmentation, typically occurring on the face, with higher prevalence in females and darker skin types. Multiple etiologies, including light exposure, hormonal influences, and family history, have been implicated in the pathogenesis of this disorder. Overall prevalence ranges widely at 1-50%, since values are typically calculated within a specific ethnic population within a geographic region. Histologically, melasma can display increased epidermal and/or dermal pigmentation, enlarged melanocytes, increased melanosomes, solar elastosis, dermal blood vessels, and, occasionally, perivascular lymphohistiocytic infiltrates. Various topical, oral, and procedural therapies have been successfully used to treat melasma. Traditional topical therapies including hydroquinone, tretinoin, corticosteroids, and triple combination creams; however, other synthetic and natural topical compounds have also shown varying efficacies. Promising oral therapies for melasma include tranexamic acid, Polypodium leucotomos, and glutathione. Procedures, including chemical peels, microneedling, radiofrequency, and lasers, are also often used as primary or adjunctive treatments for melasma. Notably, combination therapies within or across treatment modalities generally result in better efficacies than monotherapies. This review serves as a comprehensive update on the current understanding of the epidemiology, pathogenesis, clinical and histologic features of melasma, as well as treatments for this common, yet therapeutically challenging, condition.